

Application Serial No. 10/562,935  
Response

PATENT  
Docket: CU-4618

## AMENDMENTS

### Amendments to the Specification

RECEIVED  
CENTRAL FAX CENTER  
APR 17 2009

In the specification, please amend page 6, the paragraph that begins, "One embodiment of the method...", please correct line 9 as follows:

One embodiment of the method is wherein the AKG, AKG derivates or metabolites, AKG analogues or mixtures thereof are selected from the group consisting of alpha-ketoglutaric acid (AKG), ~~ornitine~~ornithine-AKG, arginine-AKG, glutamine-AKG, glutamate-AKG, leucine-AKG, chitosan-AKG and other salts of AKG with amino acids and amino acids derivates; mono- and di-metal salts of AKG such as CaAKG, Ca(AKG)<sub>2</sub>, and NaAKG.

In the specification, please amend page 11, the paragraph that begins, "According to the invention...", specifically line 29, as follows:

According to the invention, a method for decreasing absorption of plasma glucose in a ~~vetrebrate~~vertebrate, including mammal and bird, is disclosed. The method comprises administering to a ~~vertebrate~~vertebrate, including mammal and bird, in a sufficient amount and/or at a sufficient rate to enable a desired effect on glucose absorption AKG, AKG derivates or metabolites, AKG analogues or mixtures thereof.

In the specification, please amend the paragraph that begins at the bottom of page 13, line 37, and ends on page 14, line 10, beginning, "Different formats of the...", as follows:

Different formats of the parenteral food or feed supplement may be supplied, such as solid food, liquids or lyophilized or otherwise dried formulations. It may include diluents of various buffers (e.g., Tris-HCl, acetate, phosphate), pH and ionic strength, additives such as albumin or gelatine to prevent absorption to surfaces, detergents (e.g., ~~Tween20~~TWEEN20 ® (polysorbate 20), ~~Tween80~~TWEEN80 ® (polysorbate 80)),

Application Serial No. 10/562,935  
Response

PATENT  
Docket: CU-4618

~~Pluronic~~ **PLURONIC® F68 (polyoxyethylene-polyoxypropylene block copolymer)**, bile acid salts), solubilizing agents (e.g., glycerol, polyethyleneglycerol), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., Thimerosal, benzyl alcohol, parabens), bulking substances or tonicity modifiers (e.g., lactose, mannitol), covalent attachment of polymers such as polyethylene glycol to the composition, complexation with metal ions, or incorporation of the material into or onto particulate preparations of polymeric compounds such as polylactic acid, ~~polglycolic~~ **polyglycolic** acid, hydrogels, etc., or onto liposomes, microemulsions, micelles, unilamellar or multilamellar vesicles, erythrocyte ghosts, or spheroplasts.

In the specification in the paragraph beginning "According to the invention, the use..." on page 15, please amend line 29 as follows:

According to the invention, the use of AKG, AKG derivates or metabolites, AKG analogues or mixtures thereof, for the manufacture of a composition according to the invention includes an administration of a ~~therapeutical~~ **therapeutically** effective amount to the vertebrate, such as a bird or mammal in the need thereof. Such a therapeutically effective amount is about 0.01-0.2 g/kg bodyweight per daily dose.

In the specification, please amend the paragraph beginning "The vertebrate, such as..." on page 10, specifically at line 24, as follows:

The vertebrate, such as said human, may in further embodiments be any ~~vetrebrate~~ **vertebrate** in the need of increasing the availability and utilisation of amino acids, e.g. essential amino acids, or conditionally amino acids, particularly isoleucine, leucine, lysine, and proline.

Application Serial No. 10/562,935  
Response

PATENT  
Docket: CU-4618

**Amendments to the Abstract**

**Clean version**

Please replace the Abstract of the Disclosure with the following paragraph:

A method for improving absorption of amino acids in a vertebrate comprising administering to a vertebrate in a sufficient amount and/or at a sufficient rate to enable a desired effect on amino acids absorption, alpha-ketoglutarate (AKG), AKG derivatives or metabolites, AKG analogues or mixtures thereof.